Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6490887

NCCCCN.O=C(O)C(F)(F)F

nearest known ligand 0.50

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HRH4 Q9H3N8 2/20 0.50
HRH3 Q9Y5N1 2/20 0.50
CYP2D6 P10635 1/20 0.50
NFKB1 P19838 1/20 0.50
ODC1 P11926 2/20 0.48
BLM P54132 3/20 0.48
LMNA P02545 3/20 0.48
NPSR1 Q6W5P4 2/20 0.48
THRB P10828 2/20 0.48
KMT2A Q03164 2/20 0.48
MEN1 O00255 1/20 0.48
ALDH1A1 P00352 1/20 0.48
PLG P00747 1/20 0.48
ALOX15 P16050 1/20 0.48
SLC6A2 P23975 1/20 0.48
RECQL P46063 1/20 0.48
SLC6A3 Q01959 1/20 0.48
CA12 O43570 2/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Diaminooctane SCHEMBL31657050 0.97 MEN1 (0.52) HRH4HRH3CYP2D6NFKB1ODC1
Trifluoroacetic Acid SCHEMBL31657055 0.97 MEN1 (0.52) HRH4HRH3CYP2D6NFKB1ODC1
Trifluoroacetic Acid SCHEMBL29682080 0.97 MEN1 (0.52) HRH4HRH3CYP2D6NFKB1ODC1
Trifluoroacetic Acid SCHEMBL31657036 0.97 MEN1 (0.52) HRH4HRH3CYP2D6NFKB1ODC1
Trifluoroacetic Acid SCHEMBL10619767 0.94 ODC1 (0.48) HRH4HRH3CYP2D6NFKB1ODC1
Trifluoroacetic Acid SCHEMBL3149196 0.94 ODC1 (0.48) HRH4HRH3CYP2D6NFKB1ODC1
Trifluoroacetic Acid SCHEMBL8744507 0.92 ODC1 (0.46) HRH4HRH3CYP2D6NFKB1ODC1
Trifluoroacetic Acid SCHEMBL10624638 0.89 ODC1 (0.45) HRH4HRH3CYP2D6NFKB1ODC1
5-Aminovaleric Acid SCHEMBL28804498 0.88 NFKB1 (0.73) HRH4HRH3CYP2D6NFKB1ODC1
Trifluoroacetic Acid SCHEMBL2577585 0.88 DNM1 (0.52) KMT2AMEN1ALDH1A1CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6933296-B2 Compounds effective as β2-adrenoreceptor agonists as well as PDE4-inhibitors ALTANA PHARMA B.V. (NL) 2005-08-23 US disclosed
US-20030195215-A1 Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors ALTANA PHARMA B.V. (NL) 2003-10-16 US disclosed
EP-1296956-A1 COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS ALTANA Pharma AG (DE) 2003-04-02 EP disclosed
WO-2001094319-A1 COMPOUNDS EFFECTIVE AS BETA-2-ADRENORECEPTOR AGONISTS AS WELL AS PDE4-INHIBITORS ALTANA PHARMA AG (DE) 2001-12-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030195215-A1 Compounds effective as beta-2 adrenoreceptor agonists as well pde4-inhibitors ADRB1, ADRB2, ADRA1D HRH4 122/4885HRH3 302/4885CYP2D6 1704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.